Product Overview
[Drug Name]
Generic Name: Acipimox Capsules
Trade Name: Lunan/Yiping
English Name: Acipimox Capsules
Chinese Pinyin: Aximosi Jiaonang
[Ingredients]
5-Methylpyrazinecarboxylic acid 4-oxide
[Properties]
Capsules, white powder.
[Indications]
Primary and secondary hyperlipidemia diagnosed according to the Fredrickson classification, namely, hypertriglyceridemia (type IV hyperlipoproteinemia); hypercholesterolemia (type IIa hyperlipoproteinemia); and hypertriglyceridemia and hypercholesterolemia (type IIb, type III, and type V hyperlipoproteinemia).
[Dosage and Administration]
The daily dose can be determined based on plasma triglyceride and cholesterol levels. The average daily dose is: one capsule 2-3 times daily, taken after meals. For type IV hyperlipoproteinemia, take one capsule twice daily.
For type IIβ, type III, and type V hyperlipoproteinemia, take one capsule three times daily.
For particularly severe cases, the dose may be increased according to a physician's instructions.
The total daily dose should not exceed 1200 mg, and long-term use is safe.
For patients with renal insufficiency, the dose should be adjusted based on creatinine clearance. The following dosing regimen is recommended: for creatinine clearance 80-40 ml/min, one capsule daily; for creatinine clearance 40-20 ml/min, one capsule every other day.
[Adverse Reactions]
Long-term clinical observations in a large number of patients have confirmed that this drug is well tolerated. Clinical and laboratory results have shown that acipimox capsules (Lezhiping) have no toxic effects on major organs and do not interfere with metabolic pathways (sugar and uric acid metabolism).
[Contraindications]
Do not discontinue or change the dose of this drug without consulting a physician.
[Precautions]
Before using this product, a low-cholesterol and low-fat diet should be adopted, and alcohol abuse should be stopped. For patients with renal insufficiency, reduce the dose based on creatinine level data.
[Use in Special Populations]
Precautions for children: Contraindicated.
Precautions for pregnancy and lactation: Contraindicated.
Precautions for the elderly: Not yet known.
[Drug Interactions]
1. Tell your doctor or pharmacist if you are taking any other medications, including any over-the-counter medications purchased from pharmacies, supermarkets, or health food stores. 2. No data are currently available on interactions between this product and other medications. 3. Your doctor or pharmacist may have more information on precautions when taking acipimox.
[Pharmacological Actions]
Lezhiping inhibits the release of free fatty acids from adipose tissue, lowering blood concentrations of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), and reducing diglyceride and total cholesterol levels. During treatment, Lezhiping may have a beneficial effect on high-density lipoprotein cholesterol, increasing its level. Improvements in blood lipids are usually seen within the first month of treatment. Toxicology studies in various animal species have shown that this drug has very low acute toxicity and is well tolerated by systemic and gastrointestinal effects during long-term treatment (up to 2 years). Studies on the reproductive system have shown no adverse effects on reproduction, embryos, or lactation. This drug is non-mutagenic.
Storage: Store below 30°C.
Specifications: 0.25g x 24 tablets
Packaging: Box
Expiration Date: 18 months.
Approval Number: National Medicine Standard H20010769
Manufacturer: Lunan Beite Pharmaceutical Co., Ltd.
